Open-house rebate agreement for Naproxen/Esomeprazole
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Naproxen/Esomeprazol (ATC-Code nach WHO: M01AE52)
Opportunity Score
Why this score?
Opportunity
46 / 100
Complexity
58 / 100
Risk factors
The structured data marks electronic submission as not allowed and submission method as not allowed, while the XML noti...
Key participation conditions are contained in documents not provided in the extracted text, including 'Anschreiben', 'E...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Aug 31, 2027
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Aug 2027
- Non-exclusive rebate agreement for pharmaceutical products containing Naproxen/Esomeprazole (ATC M01AE52).
- Open-House model: contract conclusion is open to all interested pharmaceutical companies that meet and accept the participation conditions.
Show full summary
This is an Open-House supply arrangement for non-exclusive pharmaceutical rebate agreements for Naproxen/Esomeprazole (ATC M01AE52) with AOK PLUS. The notice states that any interested pharmaceutical company meeting the participation conditions may join during the participation period, with no individual negotiations and no exclusivity. The contract term ends no later than 31.08.2027. Participation documents are available via DTVP, but the extracted procurement documents were not provided, so document-specific requirements could not be fully analyzed.
Risks
The structured data marks electronic submission as not allowed and submission method as not allowed, while the XML noti...
Key participation conditions are contained in documents not provided in the extracted text, including 'Anschreiben', 'E...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Applicant must be a pharmaceutical company within the meaning of § 4(18) AMG for the offered medicinal product.
Eligibility
- Submission of the completed declaration of non-existence of exclusion grounds under §§ 123, 124 GWB is required.
Administrative
- The company must meet and accept the participation conditions in the documents.
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Open-house rebate agreement for Naproxen/Esomeprazole
Single lot for a non-exclusive rebate agreement concerning the pharmaceutical product Naproxen/Esomeprazole (ATC M01AE52). Scope is supply of pharmaceutical products under an Open-House model. Place of performance is Dresden, Germany. The lot is a framework agreement/open-house style arrangement with no guaranteed minimum purchase volume and no exclusivity. Lot information comes from structured data and XML notice.
Location
Duration
Category
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Naproxen/Esomeprazol (ATC-Code nach WHO: M01AE52)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 08 Jul 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 446354-2025
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
46 / 100
Complexity
58 / 100
Risk factors
The structured data marks electronic submission as not allowed and submission method as not allowed, while the XML noti...
Key participation conditions are contained in documents not provided in the extracted text, including 'Anschreiben', 'E...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications